Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr;72(4):802-804.
doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease

Joshua Quan  1 , Christopher Ma  1 , Remo Panaccione  1 , Lindsay Hracs  1 , Nastaran Sharifi  1 , Michelle Herauf  1 , Ante Makovinović  1 , Stephanie Coward  1 , Joseph W Windsor  1 , Léa Caplan  1 , Richard J M Ingram  1 , Jamil N Kanji  2   3   4 , Graham Tipples  2   5 , Jessalyn K Holodinsky  6 , Charles N Bernstein  7 , Douglas J Mahoney  8 , Sasha Bernatsky  9 , Eric I Benchimol  10   11   12 , Gilaad G Kaplan  13 ; STOP COVID-19 in IBD Research Group
Collaborators, Affiliations
Comment

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease

Joshua Quan et al. Gut. 2023 Apr.
No abstract available

Keywords: COVID-19; CROHN'S DISEASE; ULCERATIVE COLITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: GGK has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, Amgen and Takeda. He has received research support from Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck and Shire. He has been a consultant for Gilead. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018. CNB is supported by the Bingham Chair in Gastroenterology. CNB has served on advisory Boards for AbbVie Canada, Amgen Canada, Avir Pharmaceuticals, Bristol Myers Squibb Canada, Roche Canada, JAMP Pharmaceuticals Canada, Janssen Canada, Sandoz Canada, Takeda Canada and Pfizer Canada; Consultant for Mylan Pharmaceuticals and Takeda; Educational grants from Abbvie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada. Speaker’s panel for Abbvie Canada, Janssen Canada, and Takeda Canada. Received research funding from Abbvie Canada, Amgen Canada, Sandoz Canada and Pfizer Canada. CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Ferring, Janssen, Takeda, and Pfizer; research support from Ferring, Pfizer. RP has received consulting fees, speaker fees and research support from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresnius Kabi, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB and Takeda Pharmaceuticals. EIB has acted as a legal consultant for Hoffman La-Roche Limited and Peabody & Arnold LLP for matters unrelated to a medication used to treat IBD.

Figures

Figure 1
Figure 1
Concentration of antibodies to the S1 subunit of the spike protein (anti-S) by days after third-dose vaccination. Blue points represent individuals with prior SARS-CoV-2 infection. Solid red line represents the line of best fit for linear relationship between anti-S concentration (AU/mL) and time after vaccination. Solid blue line represents the threshold for positive seroconversion (50 AU/mL). Serological data from this study are available in an open access online interactive ShinyApp: https://kaplan-gi.shinyapps.io/COVID_Serology/
See this image and copyright information in PMC

Comment on

References

    1. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021;70:1884–93. 10.1136/gutjnl-2021-324789 - DOI - PubMed
    1. Lin S, Kennedy NA, Saifuddin A, et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun 2022;13:1379. 10.1038/s41467-022-28517-z - DOI - PMC - PubMed
    1. Sakuraba A, Luna A, Micic D. Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology 2022;162:88–108. 10.1053/j.gastro.2021.09.055 - DOI - PMC - PubMed
    1. Jena A, James D, Singh AK, et al. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2022;21. 10.1016/j.cgh.2022.02.030 - DOI - PMC - PubMed
    1. Murthy SK, Kuenzig ME, Windsor JW, et al. Crohn's and colitis Canada's 2021 impact of COVID-19 and inflammatory bowel disease in Canada: COVID-19 Vaccines-Biology, current evidence and recommendations. J Can Assoc Gastroenterol 2021;4:S54–60. 10.1093/jcag/gwab033 - DOI - PMC - PubMed

Substances

Grants and funding